These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 30927174)

  • 41. Change in Neutrophil-to-lymphocyte Ratio in Response to Targeted Therapy for Metastatic Renal Cell Carcinoma as a Prognosticator and Biomarker of Efficacy.
    Templeton AJ; Knox JJ; Lin X; Simantov R; Xie W; Lawrence N; Broom R; Fay AP; Rini B; Donskov F; Bjarnason GA; Smoragiewicz M; Kollmannsberger C; Kanesvaran R; Alimohamed N; Hermanns T; Wells JC; Amir E; Choueiri TK; Heng DY
    Eur Urol; 2016 Aug; 70(2):358-64. PubMed ID: 26924770
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Predictive value of C-reactive protein in patients treated with sunitinib for metastatic clear cell renal cell carcinoma.
    Pilskog M; Beisland C; Akslen LA; Bostad L; Haug Å; Heinrich D; Hjelle KM; Straume O
    BMC Urol; 2017 Aug; 17(1):74. PubMed ID: 28859644
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Neutrophil-to-lymphocyte Ratio, Platelet-to-lymphocyte Ratio, and C-reactive Protein as New and Simple Prognostic Factors in Patients With Metastatic Renal Cell Cancer Treated With Tyrosine Kinase Inhibitors: A Systemic Review and Meta-analysis.
    Semeniuk-Wojtaś A; Lubas A; Stec R; Syryło T; Niemczyk S; Szczylik C
    Clin Genitourin Cancer; 2018 Jun; 16(3):e685-e693. PubMed ID: 29454639
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prognostic value of hematologic parameters in patients with metastatic renal cell carcinoma using tyrosine kinase inhibitors.
    Gunduz S; Mutlu H; Uysal M; Coskun HS; Bozcuk H
    Asian Pac J Cancer Prev; 2014; 15(8):3801-4. PubMed ID: 24870797
    [TBL] [Abstract][Full Text] [Related]  

  • 45. C-Reactive Protein Levels and Survival Following Cytoreductive Nephrectomy in 118 Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib: A Retrospective Study.
    Xu WH; Wang J; Huo DZ; Yin GC; Cao DL; Shi GH; Qu YY; Ye DW; Zhang HL
    Med Sci Monit; 2019 Nov; 25():8984-8994. PubMed ID: 31769434
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Real-world Effectiveness and Safety of Pazopanib in Patients With Intermediate Prognostic Risk Advanced Renal Cell Carcinoma.
    Procopio G; Bamias A; Schmidinger M; Hawkins R; Sánchez AR; Estevez SV; Srihari N; Kalofonos H; Bono P; Pisal CB; Hirschberg Y; Dezzani L; Ahmad Q; Rodriguez CS; Jonasch E
    Clin Genitourin Cancer; 2019 Jun; 17(3):e526-e533. PubMed ID: 31196680
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Incorporating Neutrophil-to-lymphocyte Ratio and Platelet-to-lymphocyte Ratio in Place of Neutrophil Count and Platelet Count Improves Prognostic Accuracy of the International Metastatic Renal Cell Carcinoma Database Consortium Model.
    Chrom P; Stec R; Bodnar L; Szczylik C
    Cancer Res Treat; 2018 Jan; 50(1):103-110. PubMed ID: 28253564
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Patients with Metastatic Renal Cell Carcinoma.
    Parosanu AI; Pirlog CF; Slavu CO; Stanciu IM; Cotan HT; Vrabie RC; Popa AM; Olaru M; Iaciu C; Bratu LI; Baicoianu IF; Moldoveanu O; Baston C; Nițipir C
    Curr Oncol; 2023 Feb; 30(2):2457-2464. PubMed ID: 36826148
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials.
    Heng DY; Choueiri TK; Rini BI; Lee J; Yuasa T; Pal SK; Srinivas S; Bjarnason GA; Knox JJ; Mackenzie M; Vaishampayan UN; Tan MH; Rha SY; Donskov F; Agarwal N; Kollmannsberger C; North S; Wood LA
    Ann Oncol; 2014 Jan; 25(1):149-54. PubMed ID: 24356626
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study.
    Voss MH; Reising A; Cheng Y; Patel P; Marker M; Kuo F; Chan TA; Choueiri TK; Hsieh JJ; Hakimi AA; Motzer RJ
    Lancet Oncol; 2018 Dec; 19(12):1688-1698. PubMed ID: 30416077
    [TBL] [Abstract][Full Text] [Related]  

  • 51. C-reactive protein/albumin ratio is a predictive factor for prognosis in patients with metastatic renal cell carcinoma.
    Konishi S; Hatakeyama S; Tanaka T; Ikehata Y; Tanaka T; Hamano I; Fujita N; Yoneyama T; Yamamoto H; Yoneyama T; Hashimoto Y; Yoshikawa K; Kawaguchi T; Masumori N; Kitamura H; Ohyama C
    Int J Urol; 2019 Oct; 26(10):992-998. PubMed ID: 31342557
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The effect of kinetics of C-reactive protein in the prediction of overall survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitor.
    Teishima J; Kobatake K; Shinmei S; Inoue S; Hayashi T; Ohara S; Mita K; Hasegawa Y; Maruyama S; Kajiwara M; Shigeta M; Mochizuki H; Moriyama H; Fujiwara S; Matsubara A
    Urol Oncol; 2017 Nov; 35(11):662.e1-662.e7. PubMed ID: 28778585
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Predictive value of De Ritis ratio in metastatic renal cell carcinoma treated with tyrosine-kinase inhibitors.
    Janisch F; Klotzbücher T; Marks P; Kienapfel C; Meyer CP; Yu H; Fühner C; Hillemacher T; Mori K; Mostafei H; Shariat SF; Fisch M; Dahlem R; Rink M
    World J Urol; 2021 Aug; 39(8):2977-2985. PubMed ID: 33649869
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical and laboratory prognostic factors in patients with metastatic renal cell carcinoma treated with sunitinib and sorafenib after progression on cytokines.
    Poprach A; Pavlik T; Melichar B; Kubackova K; Bortlicek Z; Svoboda M; Lakomy R; Vyzula R; Kiss I; Dusek L; Buchler T;
    Urol Oncol; 2014 May; 32(4):488-95. PubMed ID: 24321257
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model.
    de Velasco G; Culhane AC; Fay AP; Hakimi AA; Voss MH; Tannir NM; Tamboli P; Appleman LJ; Bellmunt J; Kimryn Rathmell W; Albiges L; Hsieh JJ; Heng DY; Signoretti S; Choueiri TK
    Oncologist; 2017 Mar; 22(3):286-292. PubMed ID: 28220024
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prognostic role of N-Acetylgalactosaminyltransferase 10 in metastatic renal cell carcinoma.
    Liu L; Xiong Y; Xi W; Wang J; Qu Y; Lin Z; Chen X; Yao J; Xu J; Guo J
    Oncotarget; 2017 Feb; 8(9):14995-15003. PubMed ID: 28122358
    [TBL] [Abstract][Full Text] [Related]  

  • 57. External validation of the systemic immune-inflammation index as a prognostic factor in metastatic renal cell carcinoma and its implementation within the international metastatic renal cell carcinoma database consortium model.
    Chrom P; Zolnierek J; Bodnar L; Stec R; Szczylik C
    Int J Clin Oncol; 2019 May; 24(5):526-532. PubMed ID: 30604160
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Expression of PBRM1 as a prognostic predictor in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitor.
    Cai W; Wang Z; Cai B; Yuan Y; Kong W; Zhang J; Chen Y; Liu Q; Huang Y; Huang J; Xue W
    Int J Clin Oncol; 2020 Feb; 25(2):338-346. PubMed ID: 31720994
    [TBL] [Abstract][Full Text] [Related]  

  • 59. SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11).
    Retz M; Bedke J; Bögemann M; Grimm MO; Zimmermann U; Müller L; Leiber C; Teber D; Wirth M; Bolenz C; van Alphen R; De Santis M; Beeker A; Lehmann J; Indorf M; Frank M; Bokemeyer C; Gschwend JE
    Eur J Cancer; 2019 Jan; 107():37-45. PubMed ID: 30529901
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Sequential targeted therapy after pazopanib therapy in patients with metastatic renal cell cancer: efficacy and toxicity.
    Bellmunt J; Pons F; Foreshew A; Fay AP; Powles T; Porta C; Bracarda S; Lampron ME; Cerbone L; Sternberg CN; Hutson TE; Choueiri TK
    Clin Genitourin Cancer; 2014 Aug; 12(4):262-9. PubMed ID: 24795159
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.